The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. Systemic delivery continues to represent an area of significant opportunity. Products and product candidates in this category include inhaled drugs for the treatment of such diverse conditions as pulmonary arterial hypertension, neurological disorders, hereditary diseases and pain management.
What You Will Learn
- Which therapeutic drugs are delivered via aerosol inhalers, dry powder inhalation and nebulizers for upper respiratory conditions? For systemic delivery?
- What are the inhalable drugs currently in development, their formulation and device strategies, and targeted indication(s) and what are market prospects?
- What are the key inhalation device technologies for commercial and development-stage devices, and what are the product technology issues and related market factors?
- What are the current market dynamics of inhaled drug targeted disease segments, and what are the growth prospects and market potential for inhaled therapeutic drugs?
- What is the current market share for inhaled drugs by product? By supplier? What will it be in seven years?
- Who are the Inhaled drug product market participants, their products, market strategies, product development activity, and partners?